BCR and chronic myelogenous leukemia, BCR-ABL1 positive: Tyrosine kinase inhibitors (TKIs) such as imatinib mesylate (IM) is a targeted molecular drug that serves as frontline therapy for all phases of CML that works by binding to the tyrosine kinase domain of BCR-ABL and inhibiting its function [18].